Biohaven Enters Drug License Agreement With SK Biopharmaceuticals
Biohaven Ltd. has entered into an exclusive license agreement with SK Biopharmaceuticals for Kv7 activators. The agreement, effective August 26, 2026, grants SKBP rights to develop, manufacture, and commercialize drugs in the CNS and oncology fields.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day